B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influ...
B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influence the outcome?
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
B cell haematological malignancies (HMs) have been described as the worst cancer type for concomitant COVID‐19 in terms of mortality, with rates up to 65%. This risk factor for COVID‐19 cannot only be explained by comorbidities and advanced age of patients, but aggravated by secondary immunodeficiency (SID). We aimed at evaluating the impact of COV...
Alternative Titles
Full title
B‐cell haematological malignancies and SARS‐CoV‐2 infection: Could immunological interventions influence the outcome?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ccaec037aacf4f7f8ac65670ed2b1924
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ccaec037aacf4f7f8ac65670ed2b1924
Other Identifiers
ISSN
2688-6146
E-ISSN
2688-6146
DOI
10.1002/jha2.249
